AURLUMYN Ordering Information

Aurlumyn is available through specialty distribution through FFF Enterprises Inc.
To order, call 1-800-843-7477 or visit BioSupply - FFF Enterprises

Please note:

AURLUMYN from Lot#AT4493B is set to expire on July 31, 2025. Due to short dating, unused product from this lot is eligible for free replacement directly from SERB Pharmaceuticals. Do not discard the unused product from this lot and contact SERB Pharmaceuticals at 844-293-0007 between July 1 and September 30, 2025 for information on how to receive your free replacement.

INDICATIONS AND IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE

AURLUMYN is a prostacyclin mimetic indicated for the treatment of severe frostbite in adults to reduce the risk of digit amputations. Effectiveness was established in young, healthy adults who suffered frostbite at high altitudes.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

AURLUMYN may cause symptomatic hypotension. Correct hypotension prior to administration of AURLUMYN. Monitor vital signs while administering AURLUMYN.

Adverse Reactions

Adverse events reported with the use of intravenous (IV) iloprost in patients with frostbite include headache, flushing, palpitations/tachycardia, nausea, vomiting, dizziness, and hypotension.

Use in Specific Populations

Advise women not to breastfeed during treatment with AURLUMYN.
The safety and efficacy of AURLUMYN in pediatric patients have not been established.
Dosage adjustment is recommended in patients with moderate or severe hepatic impairment
In patients with eGFR <30 mL/min, dosage adjustment can be considered based on tolerability. The effect of dialysis on the clearance of AURLUMYN has not been evaluated.

To report suspected adverse reactions, contact BTG at 1-877-377-3784 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see Full Prescribing Information.